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Articles
The clinical and cost-effectiveness of corticosteroid 
injection versus night splints for carpal tunnel syndrome 
(INSTINCTS trial): an open-label, parallel group, randomised 
controlled trial
Linda S Chesterton, Milica Blagojevic-Bucknall, Claire Burton, Krysia S Dziedzic, Graham Davenport, Sue M Jowett, Helen L Myers, 
Raymond Oppong, Trishna Rathod-Mistry, Danielle A van der Windt, Elaine M Hay, Edward Roddy
Summary
Background To our knowledge, the comparative effectiveness of commonly used conservative treatments for carpal 
tunnel syndrome has not been evaluated previously in primary care. We aimed to compare the clinical and cost-
effectiveness of night splints with a corticosteroid injection with regards to reducing symptoms and improving hand 
function in patients with mild or moderate carpal tunnel syndrome.
Methods We did this randomised, open-label, pragmatic trial in adults (≥18 years) with mild or moderate carpal 
tunnel syndrome recruited from 25 primary and community musculoskeletal clinics and services. Patients with a 
new episode of idiopathic mild or moderate carpal tunnel syndrome of at least 6 weeks’ duration were eligible. We 
randomly assigned (1:1) patients (permutated blocks of two and four by site) with an online web or third party 
telephone service to receive either a single injection of 20 mg methylprednisolone acetate (from 40 mg/mL) or a 
night-resting splint to be worn for 6 weeks. Patients and clinicians could not be masked to the intervention. The 
primary outcome was the overall score of the Boston Carpal Tunnel Questionnaire (BCTQ) at 6  weeks. We used 
intention-to-treat analysis, with multiple imputation for missing data, which was concealed to treatment group 
allocation. The trial is registered with the European Clinical Trials Database, number 2013-001435-48, and ClinicalTrial.
gov, number NCT02038452.
Findings Between April 17, 2014, and Dec 31, 2016, 234 participants were randomly assigned (118 to the night splint 
group and 116 to the corticosteroid injection group), of whom 212 (91%) completed the BCTQ at 6 weeks. The BCTQ 
score was significantly better at 6 weeks in the corticosteroid injection group (mean 2·02 [SD 0·81]) than the night 
splint group (2·29 [0·75]; adjusted mean difference –0·32; 95% CI –0·48 to –0·16; p=0·0001). No adverse events 
were reported.
Interpretation A single corticosteroid injection shows superior clinical effectiveness at 6 weeks compared with 
night-resting splints, making it the treatment of choice for rapid symptom response in mild or moderate carpal 
tunnel syndrome presenting in primary care.
Funding Arthritis Research UK.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Carpal tunnel syndrome is the most common com­
pression neuropathy affecting the upper limb, which 
results from entrapment of the median nerve in the 
carpal tunnel.1 Carpal tunnel syndrome adversely affects 
daily activities, limits work capacity, and impacts on 
general health and quality of life.2,3 In a primary care 
population, prevalence has been reported to be 36·08 per 
10 000 people, with an annual incidence of 19·12 per 
10 000 for men and 35·95 per 10 000 for women.4
Classically, carpal tunnel syndrome causes discomfort, 
paraesthesia, and numbness in the median nerve 
distribution. Nocturnal symptoms are often clinically 
significant causing sleep disturbance, and bilateral 
symptoms occur in more than 50% of patients.2 In 
primary care, diagnosis is based on clinical history 
and examination findings,5 with electrophysiological 
diagnostic tests requested by the clinician when a 
clinical diagnosis cannot be determined and when 
surgical management is considered for severe cases.6
No consensus exists for the best primary care manage­
ment for mild or moderate carpal tunnel syndrome. 
Mainstay treatments, supported by clinical guidelines,7,8 
include night­resting splints and local corticosteroid 
injection. In severe cases or those cases that do not 
improve with conservative treatment, surgery is con­
sidered the treatment of choice.
Systematic review evidence cites two studies, both 
assessed as low quality, which suggest night splints 
might be more effective than no active treatment in the 
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short term.9 Trials of effectiveness of splint over other 
non­surgical interventions in the longer term have 
not been identified. Systematic reviews of cortico­
steroid injection10,11 and a subsequent trial12 show strong 
evidence of effectiveness in the short term (<1 month in 
the reviews and 10 weeks in the trial) compared with 
placebo, but evidence for the long­term effects is 
insufficient.
The comparative clinical effectiveness of corticosteroid 
injection and nocturnal wrist splints has only been 
investigated in two small trials,13,14 neither of which were 
done in a primary care setting. In patients with carpal 
tunnel syndrome recruited from hospital clinics and 
confirmed by nerve conduction studies, within­group 
improvements in symptoms and electrophysiological 
findings were seen after 11 months of adherent use of 
nocturnal wrist splints (n=28) but not after a single 
corticosteroid injection (n=57).13 So and colleagues14 
investigated between­group comparisons 4 weeks after 
treatment and found that a local corticosteroid injection 
and nocturnal wrist splints (n=25 participants per group) 
were equally effective for improving symptom sev­
erity, although finger dexterity was improved with local 
corticosteroid injection.
In the INSTINCTS trial (INjection versus SplinTing in 
Carpal Tunnel Syndrome), we aimed to investigate the 
comparative clinical and cost­effectiveness of cortico­
steroid injection and night splints in primary care. 
Methods
Study design and participants
We did a pragmatic, two­arm parallel group, open­label, 
randomised controlled trial within the National Health 
Service (NHS) in 25 primary and community musculo­
skeletal clinics and services in England. The trial was 
approved by the National Research Ethics Service 
Committee North West—Liverpool (UK; reference 
13/NW/0280) and the Medicines and Healthcare products 
Regulatory Agency (European Clinical Trials Database, 
number 2013­001435­8). The full protocol has been 
published before.15
We recruited participants attending general practices 
(via their general practitioner [GP]) and community 
musculoskeletal clinics (via the treating clinician). 
Potentially eligible patients were provided with a verbal 
introduction to the trial and information leaflet by the 
GP or research clinician. Patients were eligible for 
inclusion if they were aged 18 years or older and 
presented with a new episode of primary idiopathic 
mild or moderate carpal tunnel syndrome, which had 
been present for longer than 6 weeks. A GP or trained 
clinician (physiotherapist or occupational therapist) 
made the clinical diagnosis, standardised on the basis of 
presenting symptoms, clinical history, and physical 
tests using criteria developed as part of a consensus 
survey of GPs from the UK Primary Care Rheumatology 
Society.16 Mild carpal tunnel syndrome was defined as 
intermittent paraesthesia in the distribution of the 
median nerve and moderate as constant paraesthesia, 
and reversible numbness or pain of idiopathic nature.17 
Participants with bilateral carpal tunnel syndrome 
designated their study hand on the basis of the most 
severe symptoms. We excluded participants if they had 
severe carpal tunnel syndrome exhibiting constant wrist 
and hand (specifically palm, index, or middle finger, or 
thumb) pain, numbness or sensory loss in the wrist and 
Research in context
Evidence before this study
We searched MEDLINE, Embase, CINAHL, and Web of Science 
for articles published from Jan 1, 1980 to Aug 2, 2011 
(updated on Nov 6, 2012 from 2008–12). Before this study, 
evidence for the comparative clinical or cost-effectiveness of 
night splints and corticosteroid injection in the medium term 
or in a primary care population was not robust. At the time of 
designing the INSTINCTS trial (2009–12), systematic review 
evidence for the treatment of carpal tunnel syndrome 
identified only one, small trial, done in a secondary care 
setting, of head-to-head comparison for two of the mainstay 
interventions (corticosteroid injections and night-resting 
splints) used in primary care for this syndrome. A lack of 
robust evidence of clinical effectiveness beyond the short 
term for both interventions in any settings was also identified 
with most existing trials done in secondary care, where 
patients are likely to have carpal tunnel syndrome that is of 
longer duration and less responsive to conservative 
management. No trials had assessed cost-effectiveness of 
either intervention.
Added value of this study
To our knowledge, our study is the largest trial undertaken to 
date of corticosteroid injection compared with night splints for 
carpal tunnel syndrome. We have shown clinically significant 
short-term and sustained improvements for corticosteroid 
injections compared with night splints, with no safety issues. 
This is the first study to carry out a full economic assessment 
and show that both interventions are relatively inexpensive, 
with corticosteroid injection proving cost-effective over the use 
of night splints over 6 months.
Implications of all the available evidence
In a primary care setting where most treatment for mild or 
moderate carpal tunnel syndrome is undertaken, the evidence 
now shows that a corticosteroid injection is the cost-effective 
treatment of choice for rapid and sustained symptom response 
compared with night splints. These findings provide evidence 
to support treatment decision making for policy makers, 
payers (commissioners), general practitioners, and clinicians in 
musculoskeletal services, and to offer choice to patients.
Articles
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hand (specifically palm, index, or middle finger, or 
thumb), or thenar muscle atrophy; had received a 
corticosteroid injection or night splint for carpal tunnel 
syndrome within the preceding 6 months; had previous 
surgery in the affected wrist, trauma to the affected 
hand requiring surgery, or immobilisation in the 
previous 12 months; had current or previous infection 
of the affected wrist, local or systemic sepsis or infection, 
or intercurrent illness; were pregnant or lactating; were 
in receipt of anticoagulants; had a history of hyper­
sensitivity to methylprednisolone acetate or any of its 
excipients; were allergic to any of the splint materials; 
had a history of drug or alcohol abuse; were undergoing 
ongoing litigation; or were unable to complete self­
report questionnaires written in English. Written, 
informed consent was obtained from eligible partici­
pants who were interested in taking part in the trial.15
Randomisation and masking
Participants were randomly assigned (1:1) to either 
treatment group with permutated blocks of sizes two and 
four, prestratified by research site. Randomisation was 
completed by the Keele University (Keele, UK) Clinical 
Trial Unit’s (CTU) online web or telephone randomisation 
service. The allocation sequence was not available to 
research team members. We could not mask treating 
clinicians or patients to treatment allocation, but we 
concealed the treatment group allocation during the 
analyses. A letter was sent to the GPs of all participants 
informing them of their patient’s participation in the 
trial and their treatment allocation.
Procedures
Participants recruited via GP consultation received 
the trial intervention over two appointments. Those 
participants recruited after being sent trial information by 
post received the trial intervention at one appointment.15
Participants randomly assigned to receive cortico­
steroid injection received one injection of 20 mg methyl­ 
prednisolone acetate (as 20 mg of Depo­Medrone from 
40 mg/mL; Pfizer Manufacturing Belgium NV; Puurs, 
Belgium) via a disposable needle (23G or 25G) and 
syringe which was inserted at the wrist between the 
proximal and distal wrist crease to infiltrate the carpal 
tunnel. We did not allow injections into the palm of the 
hand. Patients were treated by the diagnosing clinician 
who used a sterile no­touch technique without local 
anaesthetic. Participants were advised to wait for 30 min 
following injection and to rest the injected arm for 48 h. 
They were given two Arthritis Research UK patient 
leaflets for carpal tunnel syndrome and local cortico­
steroid injections.18,19
Participants randomly assigned to a resting night splint 
received a Beta Wrist Brace (with CE marking; Promedics 
Orthopaedic; Port Glasgow, UK), which immobilised the 
wrist in a neutral or slightly extended position (20° from 
neutral) intended to reduce pressure within the carpal 
tunnel, to wear at night for 6 weeks. The splint was fitted 
according to the size of the participant’s hand and arm 
with standard splints of differing sizes. The treating 
clinician showed the participants how to fit and remove 
the wrist splint and gave them two Arthritis Research UK 
patient leaflets: carpal tunnel syndrome and splints for 
arthritis of the hand and wrist.20 The clinician instructed 
the participants to do gentle range­of­motion exercises 
when removing the splint to prevent stiffness and 
reinforced adherence by verbal instruction. 
No other types of therapy in either group were advised 
during the first 6 weeks, except for simple analgesia 
either prescribed or bought over the counter (paracetamol 
and non­steroidal anti­inflammatory drugs). To preserve 
the pragmatic nature of the trial, participants with 
bilateral carpal tunnel syndrome were permitted treat­
ment for the non­study hand according to normal clinical 
protocols in use at the research site.
Baseline data were collected from a self­completed 
questionnaire immediately before randomisation. All 
outcome measures were also collected at 6 weeks, as the 
timepoint when further treatment is most likely to be 
considered in primary care, and 6 months by postal self­
complete questionnaire, with the exception of self­
reported adverse events, which were collected in the 
6­week questionnaire only. Non­responders to follow­
up questionnaires were sent a reminder postcard after 
2 weeks. Those individuals who did not respond after 
the reminder postcard were sent a repeat questionnaire 
after a further 2 weeks. Non­responders to the repeat 
questionnaire reminders were telephoned by the 
research nurse, who was masked to the treatment group, 
to collect the primary outcome measure. Partici pants 
who had not been successfully contacted by telephone 
after five attempts were sent a postal minimum data 
questionnaire.
Outcomes
The primary outcome was the overall score for symptom 
severity and limitations in hand function on the Boston 
Carpal Tunnel Questionnaire (BCTQ) at 6 weeks 
(appendix).21 The BCTQ is a disease­specific questionnaire 
referring to a typical 24­h period in the last 2 weeks of 
completing the questionnaire, which was done at baseline 
and all follow­up points. It consists of two subscales: 
symptom severity scale (11 items) and function status 
scale (eight items). Secondary outcome measures at 
6 weeks, 6 months, 12 months, and 24 months included 
BCTQ symptom severity and function status subscales,21 
hand–wrist symptom intensity (0–10 numerical rating 
scale), referral for surgery, surgery, and self­reported 
adherence.  Secondary outcome measures at 6 weeks and 
6 months only included interrupted sleep.22 Secondary 
measures at 6 months, 12 months, and 24 months only 
were over­the­counter and prescribed analgesia, perceived 
benefit and satisfaction with treat ment,23 impact of carpal 
tunnel syndrome on work and activities, general health 
See Online for appendix
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(EuroQoL EQ­5D­5L),24 health­care use and patient 
incurred costs, and use of co­interventions. Furthermore, 
performance at work and days off work were also 
measured at all follow­up timepoints and were used in 
sensitivity analyses (appendix). Long­term follow­up of 
12 months and 24 months will be published elsewhere 
once collection is complete in early 2019. 
Incident adverse events from either intervention were 
reported and assessed with clinical case report forms, 
participant self­report in follow­up questionnaires or 
directly to the CTU, or to their GP.
Statistical analysis
We aimed to detect a 15% greater improvement on the 
BCTQ from an expected baseline value of about 2·9 points 
(scale 1–5 [SD 1·0])12,25–27 in the corticosteroid injection 
group compared with night splinting (ie, a 0·9­point (30%) 
reduction in the injection group versus a 0·45­point (15%) 
reduction in the night splint group, with a pooled SD 
of 1·0 and standardised mean difference of 0·45). Given 
90% power, 5% two­tailed significance, and assuming 
15% loss to follow­up, 240 patients (120 in each treatment 
group) were required.
We used descriptive statistics (mean and SD or 
frequency counts and percentages, as appropriate) to 
summarise baseline characteristics of participants by 
treatment group and assess similarity of randomised 
participants with eligible non­participants. The primary 
analysis was by intention to treat and was done inde­
pendently by two statisticians, who remained masked to 
treatment allocation up until the per­protocol analysis. 
Multiple imputation with chain equations28 were used 
to impute missing data arising from questionnaire 
non­response or non­completion of all items in the 
questionnaire. Data were assumed to be missing at 
random. Multiple imputation was applied to all partici­
pants randomly assigned to treatment, and the number 
of imputations was set at 35. Results based on multiply 
imputed data were compared with those based on 
complete­case analysis as a sensitivity analysis.
The primary between­group evaluation used multiple 
linear regression to obtain the mean between­group 
difference with 95% CI in the BCTQ overall score at 
6 weeks, adjusting for age at randomisation, sex, duration 
of symptoms, and baseline BCTQ­score. As a sensitivity 
analysis, if an imbalance existed in patient characteristics 
between the treatment groups, the affected characteristics 
would be further adjusted for.
By use of linear and logistic regression models 
for continuous and dichotomous outcomes respectively, 
secondary analyses included between­group comparisons 
of the BCTQ overall score at 6 months, the BCTQ 
symptom severity and function subscales, and other 
outcome measures recorded at 6 weeks or 6 months, 
or both.
We did a per­protocol sensitivity analysis based on 
self­reported adherence to night splinting for at least 
4–6 nights per week and use of a single corticosteroid 
injection. No interim analyses were completed.
Potential effect modification was investigated for 
participants’ expectations of the probable response to 
corticosteroid injection or night­splinting treatments 
as recorded at baseline and presence of bilateral car­
pal tunnel syndrome, and analysed through adding 
moderator × treatment interactions to the models estim­
ating the primary outcome of overall BCTS score, to 
provide exploratory findings regarding subgroup effects 
at 6 weeks and 6 months.
The primary economic analysis was a cost­utility 
analysis, done from an NHS perspective, to determine 
the cost­effectiveness of night splints versus cortico­
steroid injection. Health­care resource use data were 
obtained from self­report questionnaires at 6 months 
and these were valued with unit cost data obtained from 
the British National Formulary,29 Unit Costs of Health 
and Social Care,30 and NHS reference costs.31 We also 
estimated the cost of delivering both interventions (night 
splints and corticosteroid in jections). All costs were 
valued at 2016–17 prices. Outcomes were measured in 
quality­adjusted life­ years (QALYs). We calculated 
QALYs over 6 months for each study participant using 
EQ­5D 5L scores and the area under the curve approach. 
Imbalances in baseline utility (EQ­5D) scores between 
the study arms were controlled for with a multiple linear 
regression approach. Missing cost and EQ­5D­5L scores 
were imputed with a multiple imputation approach. An 
imputation model was fitted and included 25 imputed 
datasets.
An incremental analysis was undertaken, with differ­
ences in costs and QALYs expressed as an incremental 
cost­effectiveness ratio (ICER) of cost per additional QALY 
gained. Bootstrapping was used to quantify uncertainty, 
and 5000 paired estimates of mean differential costs 
and QALYs were estimated and presented on a cost­
effectiveness plane. A cost­effectiveness acceptability curve 
was constructed to show the probability of injection 
being cost­effective across a range of possible values of 
willingness to pay for an additional QALY.
Sensitivity analysis had four main foci. First, broader 
societal costs were calculated with the human capital 
approach to determine productivity losses due to time off 
work over the 6­month period. Costs of absenteeism 
from paid work were estimated by multiplying the 
reported number of days off work by the average daily 
wage, stratified by hourly mean income according to 
sex, full­time or part­time work status, and standard 
occupational classification (2010).32 Second, sensitivity 
analysis focused on estimating the cost­effectiveness 
of the interventions from a health­care perspective (in­
cluding private health­care costs). Third, cost­utility 
analysis was done with individual­level utility scores 
obtained with the EQ­5D­5L questionnaire mapped back 
to the EQ­5D 3L valuation set, as recommended by 
National Institute for Health and Care Excellence.33 
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Finally, cost­effectiveness analysis was done with the 
BCTQ. Results were deemed statistically significant if 
p values were less than 0·05. We did all analyses using 
Stata 13.
An external trial steering and data monitoring 
committee were appointed. The trial was prospectively 
registered with ClinicalTrials.gov on Jan 16, 2014, 
(NCT02038452) and registered with Current Controlled 
Trials on May 1, 2014 (ISRCTN09392969).
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The lead author (LSC)  and data custodian (TR­M) had 
full access to all data in the trial and LSC had final 
responsibility for the decision to submit for publication.
Results
Between April 17, 2014, and Dec 31, 2016, 750 patients 
were seen at their general practice or community 
musculoskeletal clinic and assessed for eligibility, of 
whom 405 (54%) fulfilled eligibility criteria (figure 1). 
The most frequent reasons for ineligibility were that 
patients had received corticosteroid injection or night 
splints in the preceding 6 months (n=117, 26%), had 
severe carpal tunnel syndrome symptoms (n=54, 12%), 
and had intercurrent illnesses (n=53, 12%). Of the 
eligible patients, 234 gave informed consent and were 
randomly assigned to treatment (58% of 405 eligible 
patients and 31% of 750 clinical attendees); 118 to the 
night splint group and 116 to the corticosteroid injection 
group. The number of participants randomly assigned 
at each centre ranged from 0 to 36. Demographic 
charac teristics were similar between participants 
(n=234) and eligible non­participants (n=171): mean age 
52·4 years (SD 15·9) versus 53·4 years (14·7) and 
n=80 (34%) versus n=50 (29%) were men, respectively. 
Clinicians reported 22 protocol deviations (15 treatment, 
one eligibility, three data capture, two recruitment, and 
one pharmacovigilance) and participants reported 
11 self­report adherence deviations.
Most baseline characteristics were similar between 
treat ment groups, with minor imbalances; however, 
larger imbalances were observed for currently being in a 
paid job, presence of other conditions affecting the neck, 
shoulders or elbow, and how the hand or wrist problems 
started (table 1). 217 participants returned the 6­week 
questionnaire, exceeding the required sample size for the 
primary analysis of n=200 (figure 1). 193 participants (one 
withdrew) returned the 6­month questionnaire (figure 1). 
Participants lost to follow­up at 6 weeks tended to be 
younger (mean age 53·3 years [SD 15·8)] for responders 
and 40·6 years [13·4] for non­responders), more often 
men (n=72 [33%] vs n=8 [47%]), and in employment 
(n=121 [56%] vs n=11 [65%]; appendix).
At 6 weeks, a significantly greater improvement in 
overall BCTQ score was seen for the corticosteroid 
injection group (mean score 2·02 [SD 0·81]) than for 
the night splint group (2·29 [0·75]; adjusted mean 
difference –0·32; 95% CI –0·48 to –0·16; p=0·0001; 
table 2). Adjusted effect estimates for BCTQ symptom 
severity subscale, BCTQ functional status subscale, 
hand–wrist pain intensity, and insomnia due to hand or 
wrist problems were better or were less frequent in the 
injection group than the night splint group at 6 weeks 
(table 2).
At 6 months, further improvement in overall BCTQ 
score was seen in the night splint group, while the 
corticosteroid injection group on average sustained 
improvements observed at 6 weeks (figure 2). However, 
outcomes did not differ between treatment groups 
(table 2).
No serious or unexpected adverse events were reported. 
In terms of expected adverse reactions, within the 
corticosteroid injection group four (3%) participants 
reported thinning, lightening, or darkening of the skin 
at the injection site, 17 (15%) had hot flushes, and 
Figure 1: Consort flow diagram
118 allocated to night splint group
117 completed questionnaire (99%)
1 did not respond
118 sent 6-week questionnaire 
109 completed questionnaire (92%) 
7 did not respond or refused 
2 patient self-withdrawal
116 sent 6-month questionnaire 
96 completed questionnaire (83%)
1 completed questionnaire and withdrew 
17 did not respond or refused 
2 patient self-withdrawal
116 allocated to corticosteriod injection group
113 completed questionnaire (97%)
3 did not respond
171 eligible but unwilling to take part (non-participants)
34 no reason given
123 unwilling to receive intervention
10 unwilling to comply with follow-up
4 other
116 sent 6-week questionnaire
108 completed questionnaire (93%)
8 did not respond or refused 
116 sent 6-month questionnaire
96 completed questionnaire (83%)
17 did not respond or refused
3 patient self-withdrawal 
345 ineligible
71 not diagnosed with carpal tunnel syndrome
268 did not meet inclusion or met exclusion 
criteria
6 general practitioner decision patient not 
eligible
750 assessed for eligibility
405 eligible
234 randomly assigned
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53 (46%) had a more painful hand or wrist after the 
injection, of whom 18 (34%) reported the pain lasting 
more than 3 days before it started to ease. In the night 
splint group, seven (6%) were not able to wear the splints 
as instructed because the splints were uncomfortable. 
Further adjustment of the analysis of primary outcome 
for the imbalanced baseline characteristics resulted in 
negligible changes of the results (adjusted mean 
difference –0·33, 95% CI –0·51 to –0·16 for the injection 
group vs –0·32, –0·48 to –0·16 for the night splint).
The results of the sensitivity analysis comparing effect 
estimates based on multiple imputation with complete­
case analysis were similar for all outcomes at 6 weeks 
and 6 months (adjusted mean difference for overall 
Corticosteroid 
injection group 
(n=116)
Night splint 
group 
(n=118)
Demographics
Age
Mean (SD) 52·6 (17·0) 52·2 (14·9)
Median (IQR) 53·50 
(39·25–65·00)
50·00 
(40·75–64·25)
Sex
Male 43 (37%) 37 (31%)
Female 73 (63%) 81 (69%)
Previous history of carpal tunnel syndrome
First time diagnosed with carpal tunnel syndrome
Yes 97 (84%) 102 (86%)
No 16 (14%) 15 (13%)
Missing 3 (3%) 1 (1%)
Number of times previously had carpal tunnel syndrome
Not applicable 97 (84%) 102 (86%)
1 11 (9%) 8 (7%)
2 1 (1%) 1 (1%)
3 0 0
>3 3 (3%) 4 (3%)
Missing 4 (3%) 3 (3%)
Treatments for previous carpal tunnel syndrome for either hand
Not applicable 97 (84%) 102 (86%)
None 5 (4%) 8 (7%)
Steroid injection 3 (3%) 4 (3%)
Wrist splints 7 (6%) 4 (3%)
Carpal tunnel decompression 
(surgery)
3 (3%) 2 (2%)
Ultrasound 1 (1%) 1 (1%)
Exercises 0 0
Vitamin supplements 0 1 (1%)
Changes in the work place 0 0
Physiotherapy 1 (1%) 0
Current carpal tunnel syndrome
Which problematic hand or wrist? 
Right 36 (31%) 37 (31%)
Left 19 (16%) 20 (17%)
Both 57 (49%) 59 (50%)
Missing 4 (3%) 2 (2%)
If both hands problematic, which hand is worse?
Not applicable 55 (47%) 57 (48%)
Right 25 (22%) 24 (20%)
Left 13 (11%) 19 (16%)
No difference 7 (6%) 3 (3%)
Missing 16 (14%) 15 (13%)
(Table 1 continues in next column)
Corticosteroid 
injection group 
(n=116)
Night splint 
group 
(n=118)
(Continued from previous column)
Duration of hand or wrist problems
<3 months 19 (16%) 17 (14%)
3–6 months 37 (32%) 33 (28%)
6 months to 1 year 22 (19%) 27 (23%)
>1 year 34 (29%) 39 (33%)
Missing 4 (3%) 2 (2%)
How did hand or wrist problems start?
Suddenly: symptoms developed 
quickly within a few days
33 (28%) 17 (14%)
Gradually: symptoms developed 
more slowly over weeks to months
79 (68%) 99 (84%)
Missing 4 (3%) 2 (2%)
Particular position causes hand or wrist problems
Yes 50 (43%) 62 (53%)
No 62 (53%) 54 (46%)
Missing 4 (3%) 2 (2%)
Currently taking pain relief for hand or wrist problems
Yes 36 (31%) 34 (29%)
No 77 (66%) 83 (70%)
Missing 3 (3%) 1 (1%)
Employment
In a current paid job
Yes 58 (50%) 74 (63%)
No 55 (47%) 42 (36%)
Missing 3 (3%) 2 (2%)
If not in current paid job, describe current situation
Not applicable 58 (50%) 74 (63%)
Retired 38 (33%) 29 (25%)
Student 3 (3%) 1 (1%)
Looking after children or home 12 (10%) 9 (8%)
Unemployed 3 (3%) 7 (6%)
Voluntary worker 2 (2%) 0
Missing 3 (3%) 2 (2%)
Treatment expectations
Which treatment would you prefer?
Strongly prefer wrist injection 13 (11%) 13 (11%)
Somewhat prefer wrist injection 11 (9%) 21 (18%)
No preference 65 (56%) 60 (51%)
Somewhat prefer night splints 12 (10%) 8 (7%)
Strongly prefer night splints 6 (5%) 10 (8%)
Missing 9 (8%) 6 (5%)
(Table 1 continues in next column)
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BCTQ score at 6 weeks –0·32, 95% CI –0·48 to –0·16 based 
on multiple imputation for 234 participants vs –0·36, 
–0·54 to –0·19 based on complete­case analysis of 197 
participants; adjusted mean difference for overall BCTQ 
score at 6 months 0·06, –0·11 to 0·23 based on multiple 
imputation for 234 participants vs 0·05, –0·13 to 0·24 
based on complete­case analysis of 175 participants).
For the per­protocol sensitivity analysis, patients whose 
treatment deviated from protocol were excluded (n=31). 
In the corticosteroid injection group, three participants 
were excluded from the analysis as they either received an 
incorrect injection (n=2) or additionally to the injection 
wore a night splint (n=1; therefore switched treatment 
group). In the night splint group, 28 partici pants were 
removed from the analysis as they received a corticosteroid 
injection in addition to the night splint (n=2; therefore 
switched treatment group), wore the splint on the wrong 
hand (n=3), did not wear the splint for at least 4–6 nights 
per week (n=4), or did not provide adherence data (n=19). 
Therefore, 89 patients in the night splint group and 
114 patients in the injection group were included in the 
per­protocol sensitivity analysis. The results were similar 
to the intention­to­treat analysis with adjusted mean 
differences for overall BCTQ scores of –0·36 (95% CI 
–0·55 to –0·18) versus –0·32 (–0·48 to –0·16; table 2) at 
6 weeks and 0·05 (–0·15 to –0·25) versus 0·06 (–0·11 to 
0·23; table 2) at 6 months. Between 6 weeks and 6 months 
after randomisation, in the injection group nine 
participants were using night splints and in the night 
splint group 12 participants had received an injection.
Exploratory, a­priori defined subgroup analysis in 
participants with unilateral and bilateral carpal tunnel 
syndrome showed no statistically significant or im­
portant effect modification on the overall BCTQ score 
(–0·14, 95% CI –0·47 to 0·19). The adjusted mean 
difference for overall BCTQ score for injection versus 
splint was –0·25 (95% CI –0·47 to –0·02) for those with 
unilateral symptoms and –0·39 (–0·62 to –0·15) for 
those with bilateral symptoms at 6 weeks. Similar results 
Corticosteroid 
injection group 
(n=116)
Night splint 
group 
(n=118)
(Continued from previous column)
If you received a wrist injection, would you expect your symptoms to 
improve?
Yes 69 (59%) 70 (59%)
No 0 2 (2%)
Not sure 39 (34%) 41 (35%)
Missing 8 (7%) 5 (4%)
If you received a night splint, would you expect your symptoms to improve?
Yes 46 (40%) 40 (34%)
No 3 (3%) 4 (3%)
Not sure 58 (50%) 69 (58%)
Missing 9 (8%) 5 (4%)
Quality of life
Have you been bothered by feeling down, depressed, or hopeless? 
Yes 47 (41%) 39 (33%)
No 66 (57%) 78 (66%)
Missing 3 (3%) 1 (1%)
Have you been bothered by little interest or pleasure in doing things?
Yes 39 (34%) 33 (28%) 
No 74 (64%) 83 (70%)
Missing 3 (3%) 2 (2%)
General health
Diagnosed with hypothyroidism
Yes 5 (4%) 9 (8%)
No (negative or never tested) 108 (93%) 107 (91%)
Missing 3 (3%) 2 (2%)
Diagnosed with diabetes
Yes 13 (11%) 8 (7%)
No 99 (85%) 109 (92%)
Missing 4 (3%) 1 (1%)
Any other conditions affecting neck, shoulders, or elbows
Yes 45 (39%) 28 (24%)
No 68 (59%) 88 (75%)
Missing 3 (3%) 2 (2%)
Had pain anywhere else apart from your hand or wrist
Yes 74 (64%) 72 (61%)
No 39 (34%) 45 (38%)
Missing 3 (3%) 1 (1%)
Last time you were free of pain anywhere
<3 months ago 22 (19%) 20 (17%)
3–6 months ago 13 (11%) 19 (16%)
6 months to 1 year ago 9 (8%) 23 (19%)
1–3 years ago 38 (33%) 23 (19%)
>3 years ago 31 (27%) 32 (27%)
Missing 3 (3%) 1 (1%)
(Table 1 continues in next column)
Corticosteroid 
injection group 
(n=116)
Night splint 
group 
(n=118)
(Continued from previous column)
On average, how often do you drink alcohol?
Daily or most days 11 (9%) 11 (9%)
Once or twice a week 38 (33%) 45 (38%)
Once or twice a month 25 (22%) 22 (19%)
Once or twice a year 16 (14%) 18 (15%)
Never 23 (20%) 21 (18%)
Missing 3 (3%) 1 (1%)
What is your current smoking status?
Never smoked 55 (47%) 55 (47%)
Previously smoked 39 (34%) 48 (41%)
Current smoker 19 (16%) 13 (11%)
Missing 3 (3%) 2 (2%)
Mean body-mass index (SD) 30·2 (7·6) 30·5 (7·5)
Data are n (%), unless otherwise stated. Data might not total 100% because of 
rounding.
Table 1: Baseline characteristics
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were obtained at 6 months for the effect modification 
(–0·15, 95% CI –0·48 to 0·19) and the adjusted mean 
difference was 0·13 (95% CI –0·10 to 0·37) for those 
with unilateral symptoms and –0·01 (–0·25 to 0·23) for 
those with bilateral symptoms.
The exploratory, a­priori defined subgroup analysis 
investigating effect modification by participants’ expec­
tations regarding treatment response showed larger 
improvements in BCTQ scores were seen in those 
allocated to the intervention of their preference (n=42, 
adjusted mean difference –0·52, 95% CI –0·93 to –0·12) 
compared with those who were not allocated to 
the intervention of their preference (n=52, –0·12, 
–0·50 to 0·26). Those individuals who preferred to have 
an injection showed larger improvements (n=58, –0·60, 
–0·97 to –0·23) than those who preferred a night splint 
(n=52, –0·22, –0·60 to 0·16) or had no preference for 
either treatment (n=128, –0·24, –0·44 to –0·05). For both 
subgroup analyses, effect modification by treatment 
expectations was not statistically significant.
With regards to the resource use, costs, and outcomes 
(EQ­5D and QALYs) over 6 months, from an NHS pers­
pective, corticosteroid injection was more costly and more 
effective (cost difference £33·54, 95% CI –94·57 to 145·59, 
QALY difference 0·008, 95% CI –0·01 to 0·02) than night 
splinting (figure 3; appendix). The resulting ICER was 
£4193 per QALY gained (table 3) with a 76% probability of 
corticosteroid injection being cost­effective at a willingness­
to­pay threshold of £20 000 per QALY gained (figure 3).
Sensitivity analysis assessing the broader societal costs 
indicated that night splinting was associated with more 
time off work and higher productivity costs (appendix). 
The results also show that corticosteroid injection was 
cost­effective (£2711 per QALY gained) from a health­care 
perspective and also cost­effective when the cross­
 Figure 2: Symptom severity and functional limitations 
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Regression analysis*
Adjusted mean difference 
(95% CI) or OR (95% CI)
p value
Overall BCTQ symptom severity and functional limitations
Baseline 2·69 (0·70) 2·65 (0·62) ·· ··
6 weeks† 2·02 (0·81) 2·29 (0·75) –0·32 (–0·48 to –0·16)‡ 0·0001
6 months 2·15 (0·79) 2·06 (0·73) 0·06 (–0·11 to 0·23) 0·499
BCTQ symptom severity scale
Baseline 2·96 (0·66) 2·91 (0·61) ·· ··
6 weeks 2·12 (0·84) 2·43 (0·76) –0·35 (–0·53 to –0·17) 0·0001
6 months 2·33 (0·86) 2·18 (0·75) 0·13 (–0·07 to 0·33) 0·209
BCTQ functional limitations
Baseline 2·32 (0·92) 2·28 (0·84) ·· ··
6 weeks 1·88 (0·88) 2·09 (0·86) –0·26 (–0·43 to –0·09) 0·0031
6 months 1·91 (0·84) 1·89 (0·84) –0·005 (–0·175 to 0·166) 0·957
Hand–wrist pain intensity
Baseline 6·33 (2·05) 6·12 (2·21) ·· ··
6 weeks 3·42 (2·77) 4·28 (2·73) –0·97 (–1·64 to –0·30) 0·0049
6 months 4·32 (3·26) 3·46 (3·01) 0·79 (–0·02 to 1·59) 0·055
Insomnia due to hand or wrist problems
Baseline 70 (60·6%) 60 (50·6%) ·· ··
6 weeks 33 (28·2%) 45 (38·3%) OR 0·44 (0·22–0·87) 0·018
6 months 37 (31·9%) 32 (27·2%) OR 1·12 (0·55–2·20) 0·755
Referral to surgery
6 weeks 4 (3·2%) 5 (4·6%) ··§ ··§
6 months 22 (18·6%) 14 (11·9%) OR 1·66 (0·73–3·77) 0·227
Surgery
6 weeks 2 (1·3%) 2 (1·8%) ··§ ··§
6 months 17 (14·3%) 13 (11·1%) OR 1·28 (0·41–3·98) 0·664
Herbal remedies and 
vitamin use at 6 months
7 (6·4%) 7 (6·0%) OR 1·43 (0·28–7·34) 0·664
Over-the-counter pain 
medication at 6 months¶ 
34 (29·5%) 30 (25·3%) OR 1·42 (0·63–3·18) 0·399
Prescribed pain medication 
at 6 months||
20 (17·5) 12 (10·6%) OR 1·99 (0·70–5·66) 0·197
Score range 1–5 (higher score indicates more severe symptoms and functional impairment). Data are mean (SD) or 
n (%). Analyses are based on multiply imputed data. BCTQ=Boston Carpal Tunnel Questionnaire. *Regression analysis 
adjusted for baseline score (if available), sex, age, and duration of symptoms. †11% difference in overall BCTQ scores 
change between baseline and 6 weeks. ‡Corresponding pooled SD 0·786. §Unable to analyse because of too few 
patients.¶Included paracetamol, ibuprofen, and paracetamol and codeine. ||Included paracetamol, ibuprofen, 
naproxen, diclofenac, codeine, tramadol, dihydrocodeine, paracetamol and codeine, paracetamol and tramadol, 
paracetamol and dextropropoxyphene, and paracetamol and dihydrocodeine.
Table 2: Comparative treatment effectiveness at 6 weeks and 6 months 
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walk tariff was used to estimate EQ­5D scores. Cost­
effectiveness analysis using the BCTQ score indicates 
that injection is associated with an ICER of £186 per unit 
reduction in BCTQ score (appendix).
Discussion
To our knowledge, this trial is the largest randomised 
comparison of the short­term and medium­term 
effectiveness of corticosteroid injection versus night splint 
for the treatment of carpal tunnel syndrome and the first 
to be done in a primary care setting; where most patients 
presenting with mild or moderate symptoms are managed. 
The results show that at 6 weeks, across all primary and 
secondary outcome measures analysed, a single injection 
of 20 mg methylprednisolone acetate led to significantly 
greater improvements in pain and function than night 
splints and that these improvements were largely sus­
tained over 6 months (with no difference between groups), 
which is beyond the active life of methyl prednisolone 
acetate. As a result of further improvements in the night 
splint group, differences at 6 months were small. The 
more rapid improvement associated with corticosteroid 
injection also leads to this treatment being more cost­
effective from both an NHS and societal perspective. 
These 6­month results add to the current inconsistent 
evidence of only short­term comparative effectiveness 
of corticosteroid injection versus night splints.13,14 Further­
more, we reported only known and expected adverse 
reactions. Methyl pred nisolone acetate has been widely 
used for many years in standard practice in both primary 
and secondary care and has a very well­established 
safety profile.
A minimally important clinical difference has not been 
published for the overall BCTQ for a comparison between 
these two interventions in primary care. We proposed a 
minimally important clinical difference based on the 
results of two available primary care­based studies34,35 (at 
the time of the sample size calculation in 2012) that 
separately investigated corticosteroid injections and 
splints and were therefore only indicative for defining the 
threshold for our study. An 11% difference in overall 
BCTQ scores was achieved against an anticipated 
15% difference and a 0·32 effect size against an 
anticipated effect size of 0·45 (table 2). However, the 
pooled SD of 0·786 is smaller than the SD used in the 
sample size calculation (1·0). Dividing the treatment 
effect (–0·32) by 0·786 gives an effect size of 0·41, which 
is approximately equal to the standardised difference of 
0·45 used in the sample size calculation. Given this and 
that findings were consistent across all primary and 
secondary outcomes with a more rapid improvement of 
symptoms with injection, we feel the results might be 
considered sufficiently clinically important by patients 
with mild–severe symptoms of carpal tunnel syndrome.
No consensus exists for the optimal dose or choice of 
corticosteroid to inject for carpal tunnel syndrome. 
One study based in secondary care36 found that higher 
doses of corticosteroid (60 mg methylprednisolone acetate) 
resulted in more patients being free from clinically 
significant symptoms than lower doses (20 mg or 40 mg) 
at 6 months (success of 73% for 60 mg, 56% for 40 mg, and 
53% for 20 mg), but there was no evidence of longer­term 
benefits at 12 months. In a second study, again in secondary 
care and in patients in whom splinting had already failed, 
improvements in symptom severity scores at 10 weeks 
were also greater in patients who received 80 mg and 
40 mg of methylprednisolone (difference in change from 
baseline –0·64, 95% CI –1·06 to –0·21; p=0·003) than in 
those who received placebo (–0·88, –1·30 to –0·46; 
p<0·001), but differences were not significant at 1 year.12 
Our study shows that a single injection of a relatively low 
dose of 20 mg methylprednisolone acetate (which reflects 
a consensus regarding usual practice for administering 
corticosteroid injection for carpal tunnel syndrome in 
primary care) produced a more rapid improvement of mild 
or moderate symptoms than use of night splints.
Landmark­guided (also known as blind) corticosteroid 
injection was used in the trial as this technique is 
the standard used in primary care where access to ultra­
sound is usually rare. Unguided corticosteroid injections 
have been shown to be of similar efficacy to ultrasound­
guided injections in reducing symptoms and improving 
function and electrophysiological findings in carpal 
tunnel syndrome.37
Carpal tunnel syndrome is routinely classified as mild, 
moderate, or severe, although criteria for this categori­
sation are not well established and there is lack of 
an accepted gold standard for diagnosis particularly in 
relation to the inclusion of electrophysiological tests. In 
some countries, including the UK, primary care access to 
nerve conduction studies is variable or limited. As such, 
these investigations are usually reserved for indetermin­
ate diagnoses and are not always required routinely in 
primary care for mild or moderate cases to guide decisions 
regarding initial conservative treatments.6 For the purposes 
of this trial, we felt it was important to develop a tool to 
standardise the diagnosis of carpal tunnel syndrome 
presenting in primary care. A full description of the design 
of this tool has been published elsewhere.16
Strengths of our trial include the large sample size, 
length of follow­up, and full health economic analysis. 
To answer our pragmatic research question regarding 
comparative effectiveness, it was crucial to do the trial in 
Corticosteroid 
injection group 
(n=116)
Night splint group 
(n=118)
Difference (95% CI) ICER
Mean costs (SD) £346·78 (467·97) £313·24 (480·84) £33·54 (–94·57 to 145·59) £4193 per 
QALY gained
Mean QALYs* (SD) 0·404 0·396 0·008 (–0·01 to 0·02) ··
ICER=incremental cost-effectiveness ratio. QALY=quality-adjusted life-year. *Adjusted for baseline utility. 
Table 3: Cost-utility analysis for injection versus splinting
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a setting very close to routine primary care. To optimise 
the generalisability of the findings, maximise recruit­
ment, and achieve realistic recruitment targets, we 
decided to also recruit from community­based musculo­
skeletal services, which receive direct referrals from 
multiple GPs who themselves do not inject patients 
with carpal tunnel syndrome. The characteristics of our 
trial population were similar to eligible non­participants, 
which strengthens the generalisability of our findings, 
with most participants having their first episode of 
carpal tunnel syndrome with symptoms for at least 
3 months. Trial participants and clinicians were not 
masked to treatment allocation, which is common to 
many trials of non­pharmacological interventions, and 
was inherent to the research question and pragmatic 
design of our trial. Limitations of our trial include the 
absence of a no­treatment control group, or a group 
receiving both interventions, which is not uncommon in 
primary care. We felt it was important to offer treatment 
to all participants consulting for mild or moderate 
symptoms, and adding a third group would have 
increased sample size and compromised the feasibility 
of the trial in a primary care setting. A clinical assessment 
was not included at follow­up so we are unable to 
comment on changes in clinical findings. The recruit­
ment period ended before randomisation of the target of 
240 participants, which did not compromise statistical 
power because of high follow­up, but did mean that 
the block randomisation sequence was not completed, 
leading to a minor imbalance in the number of partici­
pants in the treatment groups (n=2). 
In summary, a single corticosteroid injection shows 
superior clinical effectiveness at 6 weeks and is cost­
effective over 6 months compared with night resting 
splints, which should make it the treatment of choice 
for rapid and sustained symptom response in mild or 
moderate carpal tunnel syndrome presenting in primary 
care. These findings inform evidence­based treatment 
choices for GPs and clinicians in community musculo­
skeletal services.
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